Cyclophosphamide Is Associated with Pulmonary Function and Survival Benefit in Patients with Scleroderma and Alveolitis
- 20 June 2000
- journal article
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 132 (12), 947-954
- https://doi.org/10.7326/0003-4819-132-12-200006200-00004
Abstract
Lung inflammation (alveolitis) may cause lung fibrosis in scleroderma. To determine whether cyclophosphamide treatment is associated with retention of lung function and improved survival in scleroderma patients with alveolitis. Retrospective cohort study. Johns Hopkins and University of Maryland Scleroderma Center. 103 patients with scleroderma who had bronchoalveolar lavage or lung biopsy. Cyclophosphamide therapy. 1) Serial measurement of forced vital capacity [FVC] and carbon monoxide diffusing capacity and 2) survival. During a median follow-up of 13 months after bronchoalveolar lavage or biopsy, patients with alveolitis who did not receive cyclophosphamide therapy experienced a decrease in FVC (mean difference, −0.28 L [95% CI, −0.41 to −0.16 L] and −7.1% of the predicted value [CI, −10.9% to −4.0%]). Carbon monoxide diffusing capacity also decreased in these patients (mean difference, −3.3 mmol · min −1 · kPa −1 [CI, −4.6 to −2.1 mmol · min −1 ·kPa −1] and −9.6% of the predicted value [CI, −16.7% to −2.4%]). During a median follow-up of 16 months, patients with alveolitis who received cyclophosphamide were more likely to have a good outcome (stabilization or improvement) in FVC (relative risk, 2.5 [CI, 1.5 to 4.1]) and diffusing capacity (relative risk, 1.5 [CI, 1.0 to 2.2]). These patients also had improved survival; the median survival rate was 89% (25th, 75th percentiles, 84%, 94%) compared with 71% (25th, 75th percentiles, 55%, 86%) in untreated patients (P = 0.01, log-rank test). The presence of lung inflammation identifies patients with scleroderma who are more likely to have worsening lung function. Lung function outcomes and survival are improved in patients with alveolitis who receive cyclophosphamide.This publication has 14 references indexed in Scilit:
- American Thoracic Society. Single-breath carbon monoxide diffusing capacity (transfer factor). Recommendations for a standard technique--1995 update.American Journal of Respiratory and Critical Care Medicine, 1995
- Standardization of Spirometry, 1994 Update. American Thoracic Society.American Journal of Respiratory and Critical Care Medicine, 1995
- Fibrosing alveolitis in systemic sclerosis. Bronchoalveolar lavage findings in relation to computed tomographic appearance.American Journal of Respiratory and Critical Care Medicine, 1994
- Interrelationships Between Pulmonary and Extrapulmonary Involvement in Systemic SclerosisSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 1994
- Mast Cells' Contribution to the Fibrosing Alveolitis of the Scleroderma LungAmerican Review of Respiratory Disease, 1993
- Structural Features of Interstitial Lung Disease in Systemic SclerosisAmerican Review of Respiratory Disease, 1991
- Evaluation and management of scleroderma lung disease using bronchoalveolar lavageAmerican Journal Of Medicine, 1990
- Pharmacologic Suppression of the Neutrophil Component of the Alveolitis in Idiopathic Pulmonary FibrosisAmerican Review of Respiratory Disease, 1987
- Carbon monoxide diffusing capacity as predictor of outcome in systemic sclerosisAmerican Journal Of Medicine, 1984
- Preliminary criteria for the classification of systemic sclerosis (scleroderma)Arthritis & Rheumatism, 1980